The company’s broader OX2R portfolio includes clinical and preclinical assets with potential applications across neurological, neurodegenerative, and neuropsychiatric conditions
The company now offers the complete range of Apomorphine Hydrochloride in different fill volumes
Broadens downstream purification portfolio with next-generation Protein A chromatography for scalable manufacturing
The investigational new drug application with FDA was actually for NEOK002, an EGFR/MUC1-targeting antibody-drug conjugate aimed at solid tumors
The US FDA has approved PONLIMSI (denosumab-adet) as a biosimilar to Prolia
Sugammadex injection is bioequivalent to Merck’s Bridion injection for the reversal of neuromuscular blockade induced by rocuronium bromide and vecuronium bromide in adults and pediatric patients aged 2 years and older undergoing surgery
This strategic acquisition enables CORONA Remedies to penetrate deeper into targeted specialty and offer wider accessibility
The partnership has already launched with five active development programs, with both organizations jointly managing regulatory strategy and documentation under a structured, milestone-gated framework
Price of the starting dose of Ozempic and Wegovy reduced by 36% and 48% respectively
The approval covers pediatric patients without a matched sibling donor for stem cell transplant
Subscribe To Our Newsletter & Stay Updated
